A nasal vaccine platform for inducing robust local and systemic immunity against respiratory viral infections

This technology is a nasal influenza vaccine that uses a specially engineered protein to target a natural receptor in the respiratory tract, enabling strong local and systemic immune responses and providing effective, long-lasting protection against flu infection.

Background

The respiratory tract serves as the primary gateway for airborne pathogens such as the influenza virus, which poses a significant global health threat through widespread infection and severe illness. There is an ongoing need for more effective vaccination strategies capable of providing robust and localized protection against these respiratory pathogens. Current immunization approaches often exhibit limitations in preventing initial viral entry and subsequent transmission at mucosal surfaces, underscoring a critical gap in public health defenses.

Existing conventional influenza vaccines, typically administered through intramuscular injection, are designed to induce strong systemic immune responses throughout the body. However, a major drawback is their relative inefficiency in generating potent mucosal immunity directly within the respiratory tract. This deficiency means these vaccines offer inadequate protection at the precise anatomical site where initial infection and viral replication occur, thereby failing to effectively prevent the initial acquisition and onward spread of the virus.

Technology

This nasal formulation is an advanced influenza vaccine comprising a fusion protein of trimeric hemagglutinin (HA) antigen and a monomeric IgG Fc fragment. It is specifically engineered to target the neonatal Fc receptor (FcRn) present on respiratory epithelial cells. This clever targeting enables the efficient transport of the HA-Fc antigen across the mucosal barrier, delivering it directly to antigen-presenting cells. Co-administered with an adjuvant, CpG ODN 1836, this strategy elicits robust local immunity, including secretory IgA, mucosal IgG, and lung-resident memory T cells, alongside strong systemic antibody and T cell responses. This comprehensive immune activation at the primary site of infection provides significant protection against influenza by preventing initial viral infection and subsequent spread.

This technology differentiates itself by directly addressing the limitations of conventional influenza vaccines, which are typically administered parenterally and primarily induce systemic immunity with relatively poor mucosal responses. By leveraging the FcRn pathway to deliver the antigen intranasally, this approach specifically cultivates critical local immunity, such as lung-resident memory T cells and mucosal antibodies, directly at the respiratory tract—the primary site of viral entry. This localized defense, combined with systemic protection, offers a more complete and rapid protective response, making it superior at preventing initial infection and transmission compared to traditional methods that struggle to establish robust immunity at the mucosal surface.

Benefits

  • Efficient antigen delivery across the respiratory mucosa via FcRn targeting enhances vaccine uptake and immune activation.
  • Induces robust local mucosal immunity including secretory IgA, mucosal IgG, and lung-resident memory T cells for rapid protection at the infection site.
  • Generates strong systemic humoral responses with high neutralizing antibody titers and durable B cell memory.
  • Provides significant protection against lethal influenza virus challenge with reduced viral load and lung pathology.
  • Monomeric Fc fusion preserves native trimeric HA structure, promoting broadly neutralizing antibody responses.
  • Intranasal administration is non-invasive and targets the primary site of infection, potentially improving vaccine acceptance and efficacy.
  • FcRn targeting prolongs antigen half-life and facilitates uptake by antigen-presenting cells, enhancing both humoral and cellular immunity.
  • Potentially adaptable platform for universal influenza vaccines and other respiratory pathogens, with a favorable safety profile for vulnerable populations.

Applications

  • Intranasal influenza vaccination
  • Universal flu vaccine development
  • Mucosal vaccines for respiratory viruses
  • Vaccines for immunocompromised populations

Additional info

A nasal formulation combines trimeric influenza hemagglutinin (HA) antigen with a monomeric IgG Fc fragment. This construct targets the neonatal Fc receptor (FcRn) on respiratory epithelial cells, enabling transcytosis across the mucosal barrier. Co-administered with CpG adjuvant, it induces robust local and systemic immunity, including secretory IgA and lung-resident memory T cells, offering significant protection against influenza.